Zydus Lifesciences Approves €256.8 Million Acquisition of Amplitude Surgical

Strategic Move to Strengthen Global MedTech Footprint with 85.6% Stake Purchase

The board of Zydus Lifesciences Limited has approved the acquisition of an 85.6% stake in France-based Amplitude Surgical for a total of €256.8 million. This acquisition will be executed at a floor price of €6.25 per share, the company announced in an exchange filing on March 11, 2025.

The move is set to enhance Zydus Lifesciences’ global presence in the MedTech industry, leveraging Amplitude Surgical’s established market position in orthopedics and expanding its reach across Europe, Australia, and other key geographies.

Zydus Lifesciences Aims for Full Ownership and Delisting

• Zydus Lifesciences has stated that if the conditions of the tender offer are met, it plans to proceed with a compulsory acquisition of the remaining minority shareholder stakes.
• Once this process is completed, Amplitude Surgical will be delisted from Euronext Paris, making it a wholly owned subsidiary of Zydus.
• The move aligns with Zydus’ long-term strategy to integrate high-value MedTech assets into its portfolio and strengthen its presence in the orthopedics and medical technology sector.

Amplitude Surgical’s Financial Performance and Market Position

• As of June 30, 2024, Amplitude Surgical reported a turnover of €106 million.
• The company has demonstrated steady revenue growth over the years, with:
  • €106.0 million in revenue for FY2024
  • €100.2 million in FY2023
  • €87.6 million in FY2022
• The company specializes in high-quality lower-limb orthopedic products, including computer-assisted programs for knee and hip replacements.
• Amplitude Surgical has a strong market presence across France, Brazil, Australia, Germany, Switzerland, Belgium, and South Africa.

Zydus Lifesciences’ Strategic Vision for MedTech Expansion

The acquisition of Amplitude Surgical marks a pivotal step for Zydus Lifesciences in its MedTech expansion strategy. The company aims to:

1. Leverage Amplitude Surgical’s strong presence in the orthopedics market to broaden its global footprint.
2. Utilize Amplitude’s regulatory expertise and distribution networks to gain a stronger foothold in high-growth European and international MedTech markets.
3. Expand its research and development (R&D) capabilities, particularly in advanced orthopedic technology and specialized implants.

Speaking about the acquisition, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the long-term growth potential:

“We believe this was a natural extension in the field of medical technology. Our commitment to quality excellence, continuous investments in R&D, and expertise in manufacturing will guide our foray into highly specialized MedTech products, adding a new dimension to our operations. In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing, and geographies.”

Implications for Zydus Lifesciences and the MedTech Industry

This acquisition positions Zydus Lifesciences as a strong player in the global orthopedic and MedTech industry, competing with established names in the sector. The deal aligns with the company’s broader diversification strategy, moving beyond pharmaceuticals into high-margin medical technology and specialized surgical solutions.

The acquisition is expected to create new revenue streams for Zydus, strengthen its presence in the European healthcare market, and accelerate its growth in high-value medical technology segments. The deal also reinforces India’s growing role in global healthcare innovation and manufacturing.